Forty Seven Competitors

Catalent (NYSE:CTLT) and Forty Seven (NASDAQ:FTSV) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.

Insider & Institutional Ownership

97.8% of Catalent shares are owned by institutional investors. Comparatively, 71.8% of Forty Seven shares are owned by institutional investors. 1.0% of Catalent shares are owned by insiders. Comparatively, 37.4% of Forty Seven shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Catalent has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Forty Seven has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.

Profitability

This table compares Catalent and Forty Seven's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Catalent and Forty Seven's revenue, earnings per share (EPS) and valuation.

Catalent has higher revenue and earnings than Forty Seven. Forty Seven is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Catalent and Forty Seven, as provided by MarketBeat.

Catalent presently has a consensus price target of $125.1250, suggesting a potential upside of 21.84%. Given Catalent's higher possible upside, analysts clearly believe Catalent is more favorable than Forty Seven.

Summary

Catalent beats Forty Seven on 11 of the 13 factors compared between the two stocks.

Elanco Animal Health (NYSE:ELAN) and Forty Seven (NASDAQ:FTSV) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.

Insider & Institutional Ownership

86.8% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 71.8% of Forty Seven shares are owned by institutional investors. 0.1% of Elanco Animal Health shares are owned by insiders. Comparatively, 37.4% of Forty Seven shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Elanco Animal Health has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Forty Seven has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.

Profitability

This table compares Elanco Animal Health and Forty Seven's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Elanco Animal Health and Forty Seven's revenue, earnings per share (EPS) and valuation.

Elanco Animal Health has higher revenue and earnings than Forty Seven. Forty Seven is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Elanco Animal Health and Forty Seven, as provided by MarketBeat.

Elanco Animal Health presently has a consensus price target of $32.2273, suggesting a potential downside of 7.39%. Given Elanco Animal Health's higher possible upside, analysts clearly believe Elanco Animal Health is more favorable than Forty Seven.

Summary

Elanco Animal Health beats Forty Seven on 9 of the 13 factors compared between the two stocks.

Forty Seven (NASDAQ:FTSV) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Earnings and Valuation

This table compares Forty Seven and Alnylam Pharmaceuticals' top-line revenue, earnings per share and valuation.

Forty Seven has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Forty Seven is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Forty Seven and Alnylam Pharmaceuticals' net margins, return on equity and return on assets.

Insider & Institutional Ownership

71.8% of Forty Seven shares are owned by institutional investors. Comparatively, 92.4% of Alnylam Pharmaceuticals shares are owned by institutional investors. 37.4% of Forty Seven shares are owned by company insiders. Comparatively, 3.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Forty Seven has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Forty Seven and Alnylam Pharmaceuticals, as provided by MarketBeat.com.

Alnylam Pharmaceuticals has a consensus target price of $168.7333, suggesting a potential upside of 24.34%. Given Alnylam Pharmaceuticals' higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Forty Seven.

Summary

Alnylam Pharmaceuticals beats Forty Seven on 7 of the 13 factors compared between the two stocks.

Forty Seven (NASDAQ:FTSV) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Earnings and Valuation

This table compares Forty Seven and Zai Lab's top-line revenue, earnings per share and valuation.

Forty Seven has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Forty Seven, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Forty Seven and Zai Lab's net margins, return on equity and return on assets.

Insider & Institutional Ownership

71.8% of Forty Seven shares are owned by institutional investors. Comparatively, 81.3% of Zai Lab shares are owned by institutional investors. 37.4% of Forty Seven shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Forty Seven has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Forty Seven and Zai Lab, as provided by MarketBeat.com.

Zai Lab has a consensus target price of $197.8460, suggesting a potential upside of 29.37%. Given Zai Lab's higher possible upside, analysts plainly believe Zai Lab is more favorable than Forty Seven.

Summary

Zai Lab beats Forty Seven on 7 of the 12 factors compared between the two stocks.

Forty Seven (NASDAQ:FTSV) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Earnings and Valuation

This table compares Forty Seven and BioMarin Pharmaceutical's top-line revenue, earnings per share and valuation.

BioMarin Pharmaceutical has higher revenue and earnings than Forty Seven. Forty Seven is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Forty Seven and BioMarin Pharmaceutical's net margins, return on equity and return on assets.

Insider & Institutional Ownership

71.8% of Forty Seven shares are owned by institutional investors. Comparatively, 97.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 37.4% of Forty Seven shares are owned by company insiders. Comparatively, 2.2% of BioMarin Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Forty Seven has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Forty Seven and BioMarin Pharmaceutical, as provided by MarketBeat.com.

BioMarin Pharmaceutical has a consensus target price of $118.20, suggesting a potential upside of 53.65%. Given BioMarin Pharmaceutical's higher possible upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Forty Seven.

Summary

BioMarin Pharmaceutical beats Forty Seven on 11 of the 13 factors compared between the two stocks.

Forty Seven (NASDAQ:FTSV) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Earnings and Valuation

This table compares Forty Seven and Grifols' top-line revenue, earnings per share and valuation.

Grifols has higher revenue and earnings than Forty Seven. Forty Seven is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Forty Seven and Grifols' net margins, return on equity and return on assets.

Insider & Institutional Ownership

71.8% of Forty Seven shares are owned by institutional investors. Comparatively, 15.2% of Grifols shares are owned by institutional investors. 37.4% of Forty Seven shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Forty Seven has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Forty Seven and Grifols, as provided by MarketBeat.com.

Summary

Grifols beats Forty Seven on 9 of the 12 factors compared between the two stocks.